September 22, 2025 — Florida, USA — A recent real-world retrospective study of 359 adult patients with lower-risk myelodysplastic syndrome (LR-MDS) treated with erythropoiesis-stimulating agents (ESAs) reveals that over two-thirds of patients experienced ESA failure, often within eight weeks, with only about one-third achieving hematologic improvement, highlighting an urgent need for better anemia management strategies.
Science Significance
In community oncology settings, ESAs have been established treatments for anemia in LR-MDS, but this study shows that 68% of patients had ESA failure by about 56 days after initiation, while only 33.7% achieved hematologic improvement defined by hemoglobin rise or reduced red blood cell transfusion need—findings which redefine expectations for response rates and durability of ESA therapy in real life.
Regulatory Significance
Updated clinical practice guidelines (including NCCN) depend on accurate real-world evidence of treatment patterns and failure rates. These findings may prompt regulatory bodies to reassess ESA labeling, monitoring periods for response, and criteria for defining failure. They also strengthen the evidence base required for consideration of newer agents or supportive therapies in earlier treatment lines.
Business Significance
Advertisement
Pharma companies producing ESAs or developing new anemia therapies in LR-MDS may find these real-world results both a challenge and an opportunity: low response durability underscores the need for new or adjunctive treatments, while high rates of failure even after months of continued ESA use suggest market demand for more effective agents or diagnostic tools to predict response. Clinics may also look to optimize patient stratification and cost-effectiveness.
Patients’ Significance
For patients, the results mean that many may undergo ESA therapy without lasting benefit, and may continue treatment even after failure, exposing them to potential side effects and unnecessary costs. Knowing that roughly one in three will see hematologic improvement, and that many remain on treatment well beyond failure, can help inform shared decision-making, set realistic expectations, and drive earlier consideration of alternative or supportive treatments.
Policy Significance
Health policymakers and payers may use these findings to refine funding decisions and guidelines for treating LR-MDS. High failure rates suggest possible cost inefficiencies when ESAs are continued post-failure; policy could push for better monitoring frameworks, reimbursement tied to response, or incentivizing development of more durable therapies. Real-world evidence like this supports data-driven policy.
This real-world study of LR-MDS treated with ESAs brings clarity about the limitations of current anemia therapy: with failure in two-thirds of patients and modest response in only one-third, there is a clear need for new approaches. As clinical guidelines evolve, stakeholders—including physicians, pharmaceutical developers, and regulators—should consider incorporating these findings into treatment strategies, drug development priorities, and policy reforms to improve outcomes for patients with LR-MDS.
Source: Florida Cancer Specialists & Research Institute Press Release
